2026-01-30
Thailand has updated its medical device labeling and IFU regulation, which will take effect on June 20, 2026. The new regulations expand the scope to include Software as Medical Device (SaMD), reusable surgical and dental instruments, and medical device accessories. Manufacturers and Importers are granted transition period until June 20, 2028, to transition from the 2020 requirements to the new 2025 requirements. Medical device companies marketing products in Thailand must update their labeling and IFU to comply with this updated announcement by the enforcement deadline.
more
2026-01-30
The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore's Health Sciences Authority (HSA) have created a first‑of‑its‑kind Regulatory Innovation Corridor, launched on 12 December 2025. This coordinated fast‑track pathway allows developers of breakthrough medicines and medical devices to engage both regulators simultaneously. By offering coordinated feedback early in development, it seeks to streamline clinical trials, reduce duplication and accelerate patient access to promising therapies in areas such as cancer, dementia, obesity, rare diseases and advanced diagnostics. Further detail on the new fast track pathway have not yet been published by HSA.
more
2026-01-30
Recently, in the tempu bunsho (Japanese approved IFU) of pharmaceuticals containing hydroxycarbamide as the active ingredient, a warning was issued that, when taking this drug, glucose measurement results may show values higher than the actual glucose level (false high values).
Accordingly, similar warnings should also be included in the tempu bunsho of blood glucose measuring devices. Therefore, for blood glucose measuring devices using the enzyme electrode method, a voluntary review of the tempu bunsho should be conducted, and, if necessary, revisions and dissemination of information to should be implemented.
more